To Establish Whether Individuals With Premenstrual Dysphoric Disorder (PMDD) Demonstrate a Different Luteal-phase Sex Hormone Profile and Ratio Compared With Asymptomatic Controls.
Studie Overzicht
Toestand
Gedetailleerde beschrijving
Premenstrual dysphoric disorder (PMDD) is a severe cyclical disorder characterised by affective, cognitive and physical symptoms occurring during the luteal phase of the menstrual cycle and resolving shortly after the onset of menstruation. Although circulating ovarian hormone concentrations are generally considered to be within physiological reference ranges, increasing evidence suggests that altered sensitivity to normal hormonal fluctuations, rather than absolute hormone concentrations alone, may contribute to symptom development.
The progesterone-to-oestradiol ratio has been proposed as a potential biological marker of luteal hormonal balance; however, this has not been systematically evaluated in individuals with PMDD compared with asymptomatic controls.
This observational case-control study will compare serum progesterone concentrations, serum oestradiol concentrations, and the progesterone-to-oestradiol ratio during the mid-luteal phase between participants with PMDD and healthy controls. Hormone measurements will be obtained following confirmation of ovulation using a urinary luteinising hormone (LH) surge, with blood sampling performed approximately seven days after the LH surge to standardise assessment within the mid-luteal phase.
The findings will provide preliminary evidence regarding whether alterations in the progesterone-to-oestradiol ratio are associated with PMDD and may inform future mechanistic studies investigating the endocrine basis of the disorder.
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Milli Raizada, MBCHB Hons
- Telefoonnummer: +44 (0)1524 65201
- E-mail: m.raizada2@lancaster.ac.uk
Studie Locaties
-
-
Lancashire
-
Lancaster, Lancashire, Verenigd Koninkrijk, LA1 4YW
- Werving
- Lancaster University
-
Contact:
- Milli Raizazda, MBCHB Hons
- Telefoonnummer: +44 (0)1524 65201
- E-mail: m.raizada2@lancaster.ac.uk
-
Contact:
- Chris Gaffney, BSc (Hons.) MSc PhD SFHEA
- Telefoonnummer: +44 (0)1524 65201
- E-mail: c.gaffney@lancaster.ac.uk
-
Hoofdonderzoeker:
- milli raizada, MBCHB Hons
-
Onderonderzoeker:
- chris gaffney, BSc (Hons.) MSc PhD SFHEA
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
Accepteert gezonde vrijwilligers
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion criteria
- Aged 18-45 years old (adults but less than the typical perimenopausal age so there is not added bias/variable)
- Regular menstrual cycles (21-35 days for the last 3 months)
- Willing and able to complete a questionnaire (no new clinical diagnosis given)
- Use home urine LH test strips to detect ovulation
- Attend a single in person on site in Lancaster mid luteal blood test sample appointment (approx 7 days post LH surge)
- Provide written informed consent
- Have sufficient English language skills to understand the patient information
- Be either in Group 1 or group 2 Group 1 (PMDD group ie case group) - self reported prior diagnosis of PMDD made by a healthcare professional (GP, psychiatrist, gynaecologist) Group 2 (Control group ie comparison group) - no prior diagnosis of PMDD made by a healthcare professional and no history of clinically significant premenstrual mood symptoms on screening
Exclusion criteria
- Current use or use in the last 3 months of hormonal contraception such as the combined oral contraceptive pill, the progestogen only pill, the implant, the injection, hormonal coil (Mirena, Kyleena) or patch/ring.
- Current use or use in the last 3 months of any hormone replacement therapy (e.g. combined oestrogen and progesterone, oestrogen and Mirena coil combination, oestrogen alone if had a hysterectomy, or progesterone alone) or GnRH analogues use
- On a selective serotonin reuptake inhibitor (SSRI) with a recent initiation or dose change within the last 3 months
- Pregnant, breastfeeding or within 3 months post partum
- Irregular menstrual cycles (outside the 21-35 day window)
- Surgical menopause
- Premature ovarian insufficiency
- Other endocrine disorders e.g. uncontrolled thyroid disease, high prolactin, cushing's syndrome, polycystic ovarian syndrome)
- Regular systemic steroid use or use of other medications known to affect sex hormone within the last 3 months
- Severe mental health issues that impair consent or participation
- Needle phobic so that venepuncture is intolerable
- The use of the emergency contraceptive pill either 3 months prior to the study or during the study.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
|---|
|
control group
oestrogen and progesterone levels and ratios 5-7 days post ovulation
|
|
PMDD group
oestrogen and progesterone levels and ratios 5-7 days post ovulation
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
blood level
Tijdsspanne: 5-7 days post ovulation
|
progesterone
|
5-7 days post ovulation
|
|
blood level
Tijdsspanne: 5-7 days post ovulation
|
oestrogen
|
5-7 days post ovulation
|
|
blood test
Tijdsspanne: 5-7 days post ovulation
|
progesterone to oestrogen level
|
5-7 days post ovulation
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Chris Gaffney, BSc (Hons.) MSc PhD SFHEA, Lancaster University
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- v1.9.9.3 20250922
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .